You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameOrphenadrine
Accession NumberDB01173  (APRD00097)
TypeSmall Molecule
GroupsApproved
DescriptionA muscarinic antagonist used to treat drug-induced parkinsonism and to relieve pain from muscle spasm. [PubChem]
Structure
Thumb
Synonyms
2-(phenyl-o-tolylmethoxy)ethyldimethylamine
2-methyldiphenhydramine
beta-Dimethylaminoethyl 2-methylbenzhydryl ether
Dimethyl-[2-(phenyl-O-tolyl-methoxy)-ethyl]-amine
N,N-Dimethyl-2-(alpha-2-tolylbenzoyloxy)ethylamine
N,N-Dimethyl-2-(phenyl(O-tolyl)methoxy)ethanamine
N,N-Dimethyl-2-[(O-methyl-alpha-phenylbenzyl)oxy]ethylamine
o-methyldiphenhydramine
o-monomethyldiphenhydramine
Orfenadrina
ORPHENADRINE
Orphenadrinum
Phenyl-O-tolylmethyl dimethyaminoethyl ether
β-dimethylaminoethyl 2-methylbenzhydryl ether
External Identifiers Not Available
Approved Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Disipal Tab 50mgtablet50 mgoral3 M Pharmaceuticals, A Division Of 3 M Canada Company1957-12-312002-07-09Canada
Norflexliquid30 mgintramuscular; intravenousValeant Canada Lp Valeant Canada S.E.C.1961-12-312014-07-30Canada
Orphenadrine Citrate Injection, USPliquid30 mgintramuscular; intravenousSterimax Inc1996-12-02Not applicableCanada
Approved Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Orphenadrine Citratetablet, extended release100 mg/1oralDIRECT RX2014-01-01Not applicableUs
Orphenadrine Citratetablet, extended release100 mg/1oralAidarex Pharmaceuticals LLC1998-06-19Not applicableUs
Orphenadrine Citratetablet, extended release100 mg/1oralLake Erie Medical DBA Quality Care Products LLC2011-02-07Not applicableUs
Orphenadrine Citratetablet100 mg/1oralPreferred Pharmaceuticals, Inc.2000-02-15Not applicableUs
Orphenadrine Citratetablet100 mg/1oralEon Labs, Inc.2000-02-15Not applicableUs
Orphenadrine Citratetablet, extended release100 mg/1oralSTAT Rx USA LLC2000-06-23Not applicableUs
Orphenadrine Citratetablet, extended release100 mg/1oralAmerican Health Packaging2014-09-15Not applicableUs
Orphenadrine Citrateinjection30 mg/mLintramuscular; intravenousAkorn, Inc.2006-10-17Not applicableUs
Orphenadrine Citratetablet, extended release100 mg/1oralPhysicians Total Care, Inc.2000-04-17Not applicableUs
Orphenadrine Citratetablet, extended release100 mg/1oralProficient Rx LP1998-06-19Not applicableUs
Orphenadrine Citratetablet, extended release100 mg/1oralRx Change Co.2014-11-15Not applicableUs
Orphenadrine Citratetablet, extended release100 mg/1oralUnit Dose Services1998-06-19Not applicableUs
Orphenadrine Citratetablet100 mg/1oralProficient Rx LP2000-02-15Not applicableUs
Orphenadrine Citrateinjection30 mg/mLintramuscular; intravenousWatson Laboratories, Inc.2010-07-08Not applicableUs
Orphenadrine Citratetablet, extended release100 mg/1oralPd Rx Pharmaceuticals, Inc.1998-06-19Not applicableUs
Orphenadrine Citratetablet100 mg/1oralCarilion Materials Management2000-02-15Not applicableUs
Orphenadrine Citratetablet, extended release100 mg/1oralRebel Distributors Corp1998-06-19Not applicableUs
Orphenadrine Citratetablet, extended release100 mg/1oralPd Rx Pharmaceuticals, Inc.1998-06-19Not applicableUs
Orphenadrine Citratetablet, extended release100 mg/1oralbryant ranch prepack1998-06-19Not applicableUs
Orphenadrine Citratetablet100 mg/1oralLake Erie Medical DBA Quality Care Products LLC2000-02-15Not applicableUs
Orphenadrine Citratetablet, extended release100 mg/1oralBlenheim Pharmacal, Inc.2011-08-10Not applicableUs
Orphenadrine Citratetablet, extended release100 mg/1oralH.J. Harkins Company, Inc.2000-06-23Not applicableUs
Orphenadrine Citratetablet, extended release100 mg/1oralImpax Generics2000-06-23Not applicableUs
Orphenadrine Citratetablet, extended release100 mg/1oralGAVIS Pharmaceuticals, LLC1998-06-19Not applicableUs
Orphenadrine Citratetablet, extended release100 mg/1oralPreferred Pharmaceuticals, Inc.1998-06-19Not applicableUs
Orphenadrine Citrateinjection, solution30 mg/mLintramuscular; intravenousSagent Pharmaceuticals2011-10-01Not applicableUs
Orphenadrine Citratetablet, extended release100 mg/1oralClinical Solutions Wholesale1998-06-19Not applicableUs
Orphenadrine Citratetablet, extended release100 mg/1oralAv Kare, Inc.2015-11-022016-03-18Us
Orphenadrine Citratetablet, extended release100 mg/1oralDispensing Solutions, Inc.1998-06-19Not applicableUs
Orphenadrine Citratetablet, extended release100 mg/1oralSTAT Rx USA LLC2000-06-23Not applicableUs
Orphenadrine Citratetablet, extended release100 mg/1oralA S Medication Solutions Llc1998-06-19Not applicableUs
Orphenadrine Citratetablet, extended release100 mg/1oralPreferred Pharmaceuticals, Inc1998-06-19Not applicableUs
Orphenadrine Citratetablet100 mg/1oralMedsource Pharmaceuticals2000-02-15Not applicableUs
Approved Over the Counter Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Norflextablet (extended-release)100 mgoralValeant Canada Lp Valeant Canada S.E.C.1993-12-312014-07-30Canada
Orfenace Tablet 100mgtablet100 mgoralSterimax Inc1994-12-31Not applicableCanada
Sandoz Orphenadrinetablet (extended-release)100 mgoralSandoz Canada Incorporated2001-02-27Not applicableCanada
Unapproved/Other Products Not Available
International Brands
NameCompany
AntiflexNot Available
BanflexNot Available
BiorphenNot Available
DisipalNot Available
FlexojectNot Available
Mio-RelNot Available
MyolinNot Available
OrfenAceNot Available
OrfroNot Available
Brand mixtures
NameLabellerIngredients
Norgesic3 M Pharmaceuticals
Norgesic Forte3 M Pharmaceuticals
Norgesic Forte Tab3 M Pharmaceuticals, A Division Of 3 M Canada Company
Norgesic Tab3 M Pharmaceuticals, A Division Of 3 M Canada Company
Orphenadrine Citrate, Aspirin and CaffeineRebel Distributors Corp
Salts
Name/CASStructureProperties
Orphenadrine citrate
4682-36-4
Thumb
  • InChI Key: MMMNTDFSPSQXJP-UHFFFAOYNA-N
  • Monoisotopic Mass: 461.204966973
  • Average Mass: 461.5048
DBSALT000400
Orphenadrine hydrochloride
ThumbNot applicableDBSALT001021
Categories
UNIIAL805O9OG9
CAS number83-98-7
WeightAverage: 269.3813
Monoisotopic: 269.177964363
Chemical FormulaC18H23NO
InChI KeyInChIKey=QVYRGXJJSLMXQH-UHFFFAOYSA-N
InChI
InChI=1S/C18H23NO/c1-15-9-7-8-12-17(15)18(20-14-13-19(2)3)16-10-5-4-6-11-16/h4-12,18H,13-14H2,1-3H3
IUPAC Name
dimethyl({2-[(2-methylphenyl)(phenyl)methoxy]ethyl})amine
SMILES
CN(C)CCOC(C1=CC=CC=C1)C1=CC=CC=C1C
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as diphenylmethanes. These are compounds containing a diphenylmethane moiety, which consists of a methane wherein two hydrogen atoms are replaced by two phenyl groups.
KingdomOrganic compounds
Super ClassBenzenoids
ClassBenzene and substituted derivatives
Sub ClassDiphenylmethanes
Direct ParentDiphenylmethanes
Alternative Parents
Substituents
  • Diphenylmethane
  • Benzylether
  • Toluene
  • Tertiary aliphatic amine
  • Tertiary amine
  • Ether
  • Dialkyl ether
  • Hydrocarbon derivative
  • Organooxygen compound
  • Organonitrogen compound
  • Amine
  • Aromatic homomonocyclic compound
Molecular FrameworkAromatic homomonocyclic compounds
External DescriptorsNot Available
Pharmacology
IndicationIndicated for the treatment of Parkinson's disease.
PharmacodynamicsOrphenadrine is indicated as an adjunct to rest, physical therapy, and other measures for the relief of discomfort associated with acute painful musculoskeletal conditions. Orphenadrine is an anticholinergic with a predominantly central effect and only a weak peripheral effect. In addition, it has mild antihistaminic and local anaesthetic properties. Parkinson's syndrome is the consequence of a disturbed balance between cholinergic and dopaminergic neurotransmission in the basal ganglia caused by a decrease in dopamine. Orphenadrine restores the physiological equilibrium and has a favourable effect on the rigidity and tremor of Parkinson's disease and Parkinsonian syndromes. The effect is somewhat less on bradykinesia.
Mechanism of actionOrphenadrine binds and inhibits both histamine H1 receptors and NMDA receptors. It restores the motor disturbances induced by neuroleptics, in particular the hyperkinesia. The dopamine deficiency in the striatum increases the stimulating effects of the cholinergic system. This stimulation is counteracted by the anticholinergic effect of orphenadrine. It may have a relaxing effect on skeletal muscle spasms and it has a mood elevating effect.
Related Articles
AbsorptionOrphenadrine is almost completely absorbed in the gastrointestinal tract.
Volume of distributionNot Available
Protein binding95%
Metabolism

Biotransformation occurs mainly in the liver. Pharmacologically active metabolites are N-demethyl orphenadrine and N,N-didemethyl orphenadrine.

SubstrateEnzymesProduct
Orphenadrine
Not Available
N-demethyl orphenadrineDetails
Orphenadrine
Not Available
N,N-didemethyl orphenadrineDetails
Route of eliminationNot Available
Half life13-20 hours
ClearanceNot Available
ToxicityOral, mouse LD50 = 100 mg/kg; oral, rat LD50 = 255 mg/kg
Affected organisms
  • Humans and other mammals
PathwaysNot Available
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9881
Blood Brain Barrier+0.9134
Caco-2 permeable+0.8654
P-glycoprotein substrateSubstrate0.6196
P-glycoprotein inhibitor IInhibitor0.5825
P-glycoprotein inhibitor IINon-inhibitor0.6378
Renal organic cation transporterInhibitor0.7359
CYP450 2C9 substrateNon-substrate0.7658
CYP450 2D6 substrateSubstrate0.8918
CYP450 3A4 substrateSubstrate0.6958
CYP450 1A2 substrateNon-inhibitor0.6363
CYP450 2C9 inhibitorNon-inhibitor0.9191
CYP450 2D6 inhibitorInhibitor0.8949
CYP450 2C19 inhibitorNon-inhibitor0.9025
CYP450 3A4 inhibitorNon-inhibitor0.9363
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.5979
Ames testNon AMES toxic0.9133
CarcinogenicityNon-carcinogens0.6341
BiodegradationNot ready biodegradable0.9422
Rat acute toxicity2.8405 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.5224
hERG inhibition (predictor II)Inhibitor0.7052
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
ManufacturersNot Available
Packagers
Dosage forms
FormRouteStrength
Tabletoral50 mg
Liquidintramuscular; intravenous30 mg
Tabletoral
Tabletoral100 mg
Injectionintramuscular; intravenous30 mg/mL
Injection, solutionintramuscular; intravenous30 mg/mL
Tabletoral100 mg/1
Tablet, extended releaseoral100 mg/1
Tablet, multilayeroral
Tablet (extended-release)oral100 mg
Prices
Unit descriptionCostUnit
Norflex 30 mg/ml ampul14.31USD ml
Orphenadrine 30 mg/ml ampule11.25USD ml
Orphenadrine Compound-DS 50-770-60 mg tablet2.94USD tablet
Orphenadrine comp forte tablet2.84USD tablet
Norflex er 100 mg tablet2.67USD tablet
Norflex 100 mg tablet sa2.64USD tablet
Orphenadrine Citrate CR 100 mg 12 Hour tablet2.26USD tablet
Orphenadrine er 100 mg tablet2.17USD tablet
Orphenadrine citrate powder1.6USD g
Orphenadrine comp tablet1.31USD tablet
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
PatentsNot Available
Properties
StateSolid
Experimental Properties
PropertyValueSource
melting point< 25 °CPhysProp
boiling point195 °C at 1.20E+01 mm HgPhysProp
water solubilitySparingly soluble in waterNot Available
logP3.77SANGSTER (1993)
pKa8.91SANGSTER (1994)
Predicted Properties
PropertyValueSource
Water Solubility0.03 mg/mLALOGPS
logP3.5ALOGPS
logP4.17ChemAxon
logS-4ALOGPS
pKa (Strongest Basic)8.87ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count2ChemAxon
Hydrogen Donor Count0ChemAxon
Polar Surface Area12.47 Å2ChemAxon
Rotatable Bond Count6ChemAxon
Refractivity84.97 m3·mol-1ChemAxon
Polarizability31.83 Å3ChemAxon
Number of Rings2ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
Spectra
Spectrum TypeDescriptionSplash Key
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, NegativeNot Available
MSMass Spectrum (Electron Ionization)splash10-0a4i-9200000000-213fd17f1f5014e79c8bView in MoNA
References
Synthesis ReferenceNot Available
General References
  1. Ji D, Sui ZY, Ma YY, Luo F, Cui CL, Han JS: NMDA receptor in nucleus accumbens is implicated in morphine withdrawal in rats. Neurochem Res. 2004 Nov;29(11):2113-20. [PubMed:15662845 ]
External Links
ATC CodesM03BC51N04AB02M03BC01
AHFS Codes
  • 12:20.00
PDB EntriesNot Available
FDA labelDownload (247 KB)
MSDSDownload (73.6 KB)
Interactions
Drug Interactions
Drug
1,10-PhenanthrolineThe therapeutic efficacy of Orphenadrine can be decreased when used in combination with 1,10-Phenanthroline.
7-Nitroindazole7-Nitroindazole may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.
7-NitroindazoleThe risk or severity of adverse effects can be increased when Orphenadrine is combined with 7-Nitroindazole.
AcepromazineAcepromazine may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.
AcepromazineThe risk or severity of adverse effects can be increased when Orphenadrine is combined with Acepromazine.
AceprometazineAceprometazine may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.
AceprometazineThe risk or severity of adverse effects can be increased when Orphenadrine is combined with Aceprometazine.
AclidiniumAclidinium may increase the anticholinergic activities of Orphenadrine.
AclidiniumThe risk or severity of adverse effects can be increased when Orphenadrine is combined with Aclidinium.
adipiplonadipiplon may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.
adipiplonThe risk or severity of adverse effects can be increased when Orphenadrine is combined with adipiplon.
AgomelatineAgomelatine may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.
AgomelatineThe risk or severity of adverse effects can be increased when Orphenadrine is combined with Agomelatine.
AlfaxaloneAlfaxalone may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.
AlfaxaloneThe risk or severity of adverse effects can be increased when Orphenadrine is combined with Alfaxalone.
AlfentanilAlfentanil may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.
AlfentanilThe risk or severity of adverse effects can be increased when Orphenadrine is combined with Alfentanil.
AlphacetylmethadolAlphacetylmethadol may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.
AlphacetylmethadolThe risk or severity of adverse effects can be increased when Orphenadrine is combined with Alphacetylmethadol.
AlprazolamAlprazolam may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.
AlprazolamThe risk or severity of adverse effects can be increased when Orphenadrine is combined with Alprazolam.
AmbenoniumThe therapeutic efficacy of Orphenadrine can be decreased when used in combination with Ambenonium.
AmiodaroneThe metabolism of Orphenadrine can be decreased when combined with Amiodarone.
AmisulprideAmisulpride may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.
AmisulprideThe risk or severity of adverse effects can be increased when Orphenadrine is combined with Amisulpride.
AmitriptylineAmitriptyline may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.
AmitriptylineThe risk or severity of adverse effects can be increased when Orphenadrine is combined with Amitriptyline.
AmobarbitalAmobarbital may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.
AmobarbitalThe risk or severity of adverse effects can be increased when Orphenadrine is combined with Amobarbital.
AmoxapineAmoxapine may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.
AmoxapineThe risk or severity of adverse effects can be increased when Orphenadrine is combined with Amoxapine.
AmperozideAmperozide may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.
AmperozideThe risk or severity of adverse effects can be increased when Orphenadrine is combined with Amperozide.
Anisotropine MethylbromideThe risk or severity of adverse effects can be increased when Anisotropine Methylbromide is combined with Orphenadrine.
AprepitantThe serum concentration of Orphenadrine can be increased when it is combined with Aprepitant.
AripiprazoleAripiprazole may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.
AripiprazoleThe risk or severity of adverse effects can be increased when Orphenadrine is combined with Aripiprazole.
ArticaineArticaine may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.
ArticaineThe risk or severity of adverse effects can be increased when Orphenadrine is combined with Articaine.
AsenapineAsenapine may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.
AsenapineThe risk or severity of adverse effects can be increased when Orphenadrine is combined with Asenapine.
AtazanavirThe metabolism of Orphenadrine can be decreased when combined with Atazanavir.
AtomoxetineThe metabolism of Orphenadrine can be decreased when combined with Atomoxetine.
Atracurium besylateThe risk or severity of adverse effects can be increased when Atracurium besylate is combined with Orphenadrine.
AtropineThe risk or severity of adverse effects can be increased when Atropine is combined with Orphenadrine.
AzaperoneAzaperone may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.
AzaperoneThe risk or severity of adverse effects can be increased when Orphenadrine is combined with Azaperone.
AzelastineAzelastine may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.
BaclofenBaclofen may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.
BaclofenThe risk or severity of adverse effects can be increased when Orphenadrine is combined with Baclofen.
BarbitalBarbital may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.
BarbitalThe risk or severity of adverse effects can be increased when Orphenadrine is combined with Barbital.
BenactyzineThe risk or severity of adverse effects can be increased when Orphenadrine is combined with Benactyzine.
BendroflumethiazideThe serum concentration of Bendroflumethiazide can be increased when it is combined with Orphenadrine.
BenzatropineThe risk or severity of adverse effects can be increased when Benzatropine is combined with Orphenadrine.
BenzocaineBenzocaine may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.
BenzocaineThe risk or severity of adverse effects can be increased when Orphenadrine is combined with Benzocaine.
Benzyl alcoholBenzyl alcohol may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.
Benzyl alcoholThe risk or severity of adverse effects can be increased when Orphenadrine is combined with Benzyl alcohol.
BexaroteneThe serum concentration of Orphenadrine can be decreased when it is combined with Bexarotene.
BezitramideThe risk or severity of adverse effects can be increased when Orphenadrine is combined with Bezitramide.
BiperidenThe risk or severity of adverse effects can be increased when Biperiden is combined with Orphenadrine.
BoceprevirThe metabolism of Orphenadrine can be decreased when combined with Boceprevir.
BortezomibThe metabolism of Orphenadrine can be decreased when combined with Bortezomib.
BosentanThe serum concentration of Orphenadrine can be decreased when it is combined with Bosentan.
Botulinum Toxin Type AOrphenadrine may increase the anticholinergic activities of Botulinum Toxin Type A.
Botulinum Toxin Type BOrphenadrine may increase the anticholinergic activities of Botulinum Toxin Type B.
BrexpiprazoleBrexpiprazole may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.
BrexpiprazoleThe risk or severity of adverse effects can be increased when Orphenadrine is combined with Brexpiprazole.
BrimonidineBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.
BrimonidineThe risk or severity of adverse effects can be increased when Orphenadrine is combined with Brimonidine.
BromazepamBromazepam may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.
BromazepamThe risk or severity of adverse effects can be increased when Orphenadrine is combined with Bromazepam.
BrompheniramineBrompheniramine may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.
BrompheniramineThe risk or severity of adverse effects can be increased when Orphenadrine is combined with Brompheniramine.
BrotizolamBrotizolam may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.
BrotizolamThe risk or severity of adverse effects can be increased when Orphenadrine is combined with Brotizolam.
BupivacaineBupivacaine may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.
BupivacaineThe risk or severity of adverse effects can be increased when Orphenadrine is combined with Bupivacaine.
BuprenorphineBuprenorphine may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.
BuprenorphineThe risk or severity of adverse effects can be increased when Orphenadrine is combined with Buprenorphine.
BuspironeBuspirone may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.
BuspironeThe risk or severity of adverse effects can be increased when Orphenadrine is combined with Buspirone.
ButabarbitalButabarbital may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.
ButabarbitalThe risk or severity of adverse effects can be increased when Orphenadrine is combined with Butabarbital.
ButacaineButacaine may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.
ButacaineThe risk or severity of adverse effects can be increased when Orphenadrine is combined with Butacaine.
ButalbitalButalbital may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.
ButalbitalThe risk or severity of adverse effects can be increased when Orphenadrine is combined with Butalbital.
ButambenButamben may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.
ButambenThe risk or severity of adverse effects can be increased when Orphenadrine is combined with Butamben.
ButethalButethal may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.
ButethalThe risk or severity of adverse effects can be increased when Orphenadrine is combined with Butethal.
ButorphanolButorphanol may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.
ButorphanolThe risk or severity of adverse effects can be increased when Orphenadrine is combined with Butorphanol.
CarbamazepineCarbamazepine may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.
CarbamazepineThe risk or severity of adverse effects can be increased when Orphenadrine is combined with Carbamazepine.
CarbinoxamineCarbinoxamine may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.
CarbinoxamineThe risk or severity of adverse effects can be increased when Orphenadrine is combined with Carbinoxamine.
CarfentanilCarfentanil may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.
CarfentanilThe risk or severity of adverse effects can be increased when Orphenadrine is combined with Carfentanil.
CarisoprodolCarisoprodol may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.
CarisoprodolThe risk or severity of adverse effects can be increased when Orphenadrine is combined with Carisoprodol.
CeritinibThe serum concentration of Orphenadrine can be increased when it is combined with Ceritinib.
CetirizineCetirizine may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.
CetirizineThe risk or severity of adverse effects can be increased when Orphenadrine is combined with Cetirizine.
Chloral hydrateChloral hydrate may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.
Chloral hydrateThe risk or severity of adverse effects can be increased when Orphenadrine is combined with Chloral hydrate.
ChlordiazepoxideChlordiazepoxide may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.
ChlordiazepoxideThe risk or severity of adverse effects can be increased when Orphenadrine is combined with Chlordiazepoxide.
ChlormezanoneChlormezanone may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.
ChlormezanoneThe risk or severity of adverse effects can be increased when Orphenadrine is combined with Chlormezanone.
ChloroprocaineChloroprocaine may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.
ChloroprocaineThe risk or severity of adverse effects can be increased when Orphenadrine is combined with Chloroprocaine.
ChlorothiazideThe serum concentration of Chlorothiazide can be increased when it is combined with Orphenadrine.
ChlorphenamineChlorphenamine may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.
ChlorphenamineThe risk or severity of adverse effects can be increased when Orphenadrine is combined with Chlorphenamine.
ChlorphenoxamineThe risk or severity of adverse effects can be increased when Orphenadrine is combined with Chlorphenoxamine.
ChlorpromazineChlorpromazine may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.
ChlorpromazineThe risk or severity of adverse effects can be increased when Orphenadrine is combined with Chlorpromazine.
ChlorprothixeneChlorprothixene may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.
ChlorprothixeneThe risk or severity of adverse effects can be increased when Orphenadrine is combined with Chlorprothixene.
ChlorthalidoneThe serum concentration of Chlorthalidone can be increased when it is combined with Orphenadrine.
ChlorzoxazoneChlorzoxazone may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.
ChlorzoxazoneThe risk or severity of adverse effects can be increased when Orphenadrine is combined with Chlorzoxazone.
CimetropiumOrphenadrine may increase the anticholinergic activities of Cimetropium.
CinchocaineCinchocaine may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.
CinchocaineThe risk or severity of adverse effects can be increased when Orphenadrine is combined with Cinchocaine.
CitalopramThe risk or severity of adverse effects can be increased when Orphenadrine is combined with Citalopram.
ClarithromycinThe metabolism of Orphenadrine can be decreased when combined with Clarithromycin.
ClemastineClemastine may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.
ClemastineThe risk or severity of adverse effects can be increased when Orphenadrine is combined with Clemastine.
ClidiniumClidinium may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.
ClidiniumThe risk or severity of adverse effects can be increased when Orphenadrine is combined with Clidinium.
ClobazamClobazam may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.
ClobazamThe risk or severity of adverse effects can be increased when Orphenadrine is combined with Clobazam.
clomethiazoleclomethiazole may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.
clomethiazoleThe risk or severity of adverse effects can be increased when Orphenadrine is combined with clomethiazole.
ClomipramineClomipramine may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.
ClomipramineThe risk or severity of adverse effects can be increased when Orphenadrine is combined with Clomipramine.
ClonazepamClonazepam may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.
ClonazepamThe risk or severity of adverse effects can be increased when Orphenadrine is combined with Clonazepam.
ClonidineClonidine may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.
ClonidineThe risk or severity of adverse effects can be increased when Orphenadrine is combined with Clonidine.
ClorazepateClorazepate may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.
ClorazepateThe risk or severity of adverse effects can be increased when Orphenadrine is combined with Clorazepate.
ClotrimazoleThe metabolism of Orphenadrine can be decreased when combined with Clotrimazole.
ClozapineClozapine may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.
ClozapineThe risk or severity of adverse effects can be increased when Orphenadrine is combined with Clozapine.
CobicistatThe metabolism of Orphenadrine can be decreased when combined with Cobicistat.
CocaineCocaine may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.
CocaineThe risk or severity of adverse effects can be increased when Orphenadrine is combined with Cocaine.
CodeineCodeine may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.
CodeineThe risk or severity of adverse effects can be increased when Orphenadrine is combined with Codeine.
ConivaptanThe serum concentration of Orphenadrine can be increased when it is combined with Conivaptan.
CoumaphosThe therapeutic efficacy of Orphenadrine can be decreased when used in combination with Coumaphos.
CrizotinibThe metabolism of Orphenadrine can be decreased when combined with Crizotinib.
CyclizineCyclizine may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.
CyclizineThe risk or severity of adverse effects can be increased when Orphenadrine is combined with Cyclizine.
CyclobenzaprineCyclobenzaprine may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.
CyclobenzaprineThe risk or severity of adverse effects can be increased when Orphenadrine is combined with Cyclobenzaprine.
CyclopentolateThe risk or severity of adverse effects can be increased when Cyclopentolate is combined with Orphenadrine.
CyclosporineThe metabolism of Orphenadrine can be decreased when combined with Cyclosporine.
CyproheptadineCyproheptadine may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.
CyproheptadineThe risk or severity of adverse effects can be increased when Orphenadrine is combined with Cyproheptadine.
DabrafenibThe serum concentration of Orphenadrine can be decreased when it is combined with Dabrafenib.
DantroleneDantrolene may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.
DantroleneThe risk or severity of adverse effects can be increased when Orphenadrine is combined with Dantrolene.
DapiprazoleDapiprazole may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.
DapiprazoleThe risk or severity of adverse effects can be increased when Orphenadrine is combined with Dapiprazole.
DapoxetineThe risk or severity of adverse effects can be increased when Orphenadrine is combined with Dapoxetine.
DarifenacinThe risk or severity of adverse effects can be increased when Darifenacin is combined with Orphenadrine.
DarunavirThe metabolism of Orphenadrine can be decreased when combined with Darunavir.
DasatinibThe serum concentration of Orphenadrine can be increased when it is combined with Dasatinib.
DecamethoniumThe therapeutic efficacy of Orphenadrine can be decreased when used in combination with Decamethonium.
DeferasiroxThe serum concentration of Orphenadrine can be decreased when it is combined with Deferasirox.
DelavirdineThe metabolism of Orphenadrine can be decreased when combined with Delavirdine.
DemecariumThe therapeutic efficacy of Orphenadrine can be decreased when used in combination with Demecarium.
deramciclanederamciclane may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.
deramciclaneThe risk or severity of adverse effects can be increased when Orphenadrine is combined with deramciclane.
DesfluraneDesflurane may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.
DesfluraneThe risk or severity of adverse effects can be increased when Orphenadrine is combined with Desflurane.
DesipramineDesipramine may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.
DesipramineThe risk or severity of adverse effects can be increased when Orphenadrine is combined with Desipramine.
DesloratadineDesloratadine may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.
DesloratadineThe risk or severity of adverse effects can be increased when Orphenadrine is combined with Desloratadine.
DetomidineDetomidine may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.
DetomidineThe risk or severity of adverse effects can be increased when Orphenadrine is combined with Detomidine.
DexamethasoneThe serum concentration of Orphenadrine can be decreased when it is combined with Dexamethasone.
DexbrompheniramineDexbrompheniramine may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.
DexbrompheniramineThe risk or severity of adverse effects can be increased when Orphenadrine is combined with Dexbrompheniramine.
DexetimideThe risk or severity of adverse effects can be increased when Orphenadrine is combined with Dexetimide.
DexmedetomidineDexmedetomidine may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.
DexmedetomidineThe risk or severity of adverse effects can be increased when Orphenadrine is combined with Dexmedetomidine.
DextromoramideDextromoramide may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.
DextromoramideThe risk or severity of adverse effects can be increased when Orphenadrine is combined with Dextromoramide.
DextropropoxypheneDextropropoxyphene may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.
DextropropoxypheneThe risk or severity of adverse effects can be increased when Orphenadrine is combined with Dextropropoxyphene.
DezocineDezocine may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.
DezocineThe risk or severity of adverse effects can be increased when Orphenadrine is combined with Dezocine.
DiazepamDiazepam may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.
DiazepamThe risk or severity of adverse effects can be increased when Orphenadrine is combined with Diazepam.
DichlorvosThe therapeutic efficacy of Orphenadrine can be decreased when used in combination with Dichlorvos.
DicyclomineThe risk or severity of adverse effects can be increased when Dicyclomine is combined with Orphenadrine.
DifenoxinDifenoxin may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.
DifenoxinThe risk or severity of adverse effects can be increased when Orphenadrine is combined with Difenoxin.
DihydrocodeineDihydrocodeine may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.
DihydrocodeineThe risk or severity of adverse effects can be increased when Orphenadrine is combined with Dihydrocodeine.
DihydroergotamineThe metabolism of Orphenadrine can be decreased when combined with Dihydroergotamine.
DihydroetorphineDihydroetorphine may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.
DihydroetorphineThe risk or severity of adverse effects can be increased when Orphenadrine is combined with Dihydroetorphine.
DihydromorphineDihydromorphine may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.
DihydromorphineThe risk or severity of adverse effects can be increased when Orphenadrine is combined with Dihydromorphine.
DiltiazemThe metabolism of Orphenadrine can be decreased when combined with Diltiazem.
DimenhydrinateDimenhydrinate may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.
DimenhydrinateThe risk or severity of adverse effects can be increased when Orphenadrine is combined with Dimenhydrinate.
DiphenhydramineDiphenhydramine may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.
DiphenhydramineThe risk or severity of adverse effects can be increased when Orphenadrine is combined with Diphenhydramine.
DiphenoxylateDiphenoxylate may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.
DiphenoxylateThe risk or severity of adverse effects can be increased when Orphenadrine is combined with Diphenoxylate.
DonepezilThe therapeutic efficacy of Orphenadrine can be decreased when used in combination with Donepezil.
DoramectinDoramectin may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.
DoramectinThe risk or severity of adverse effects can be increased when Orphenadrine is combined with Doramectin.
DoxepinDoxepin may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.
DoxepinThe risk or severity of adverse effects can be increased when Orphenadrine is combined with Doxepin.
DoxycyclineThe metabolism of Orphenadrine can be decreased when combined with Doxycycline.
DoxylamineDoxylamine may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.
DoxylamineThe risk or severity of adverse effects can be increased when Orphenadrine is combined with Doxylamine.
DPDPEDPDPE may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.
DPDPEThe risk or severity of adverse effects can be increased when Orphenadrine is combined with DPDPE.
DronabinolDronabinol may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.
DronabinolOrphenadrine may increase the tachycardic activities of Dronabinol.
DronedaroneThe metabolism of Orphenadrine can be decreased when combined with Dronedarone.
DroperidolDroperidol may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.
DroperidolThe risk or severity of adverse effects can be increased when Orphenadrine is combined with Droperidol.
DrotebanolDrotebanol may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.
DrotebanolThe risk or severity of adverse effects can be increased when Orphenadrine is combined with Drotebanol.
DyclonineDyclonine may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.
DyclonineThe risk or severity of adverse effects can be increased when Orphenadrine is combined with Dyclonine.
EcgonineEcgonine may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.
EcgonineThe risk or severity of adverse effects can be increased when Orphenadrine is combined with Ecgonine.
ECGONINE METHYL ESTERECGONINE METHYL ESTER may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.
ECGONINE METHYL ESTERThe risk or severity of adverse effects can be increased when Orphenadrine is combined with ECGONINE METHYL ESTER.
EchothiophateThe therapeutic efficacy of Orphenadrine can be decreased when used in combination with Echothiophate.
EdrophoniumThe therapeutic efficacy of Orphenadrine can be decreased when used in combination with Edrophonium.
EfavirenzEfavirenz may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.
EfavirenzThe risk or severity of adverse effects can be increased when Orphenadrine is combined with Efavirenz.
EluxadolineOrphenadrine may increase the constipating activities of Eluxadoline.
EnfluraneEnflurane may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.
EnfluraneThe risk or severity of adverse effects can be increased when Orphenadrine is combined with Enflurane.
EntacaponeEntacapone may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.
EntacaponeThe risk or severity of adverse effects can be increased when Orphenadrine is combined with Entacapone.
EnzalutamideThe serum concentration of Orphenadrine can be decreased when it is combined with Enzalutamide.
ErythromycinThe metabolism of Orphenadrine can be decreased when combined with Erythromycin.
EscitalopramThe risk or severity of adverse effects can be increased when Orphenadrine is combined with Escitalopram.
Eslicarbazepine acetateThe serum concentration of Orphenadrine can be decreased when it is combined with Eslicarbazepine acetate.
EstazolamEstazolam may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.
EstazolamThe risk or severity of adverse effects can be increased when Orphenadrine is combined with Estazolam.
EszopicloneEszopiclone may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.
EszopicloneThe risk or severity of adverse effects can be increased when Orphenadrine is combined with Eszopiclone.
EthanolEthanol may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.
EthchlorvynolEthchlorvynol may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.
EthchlorvynolThe risk or severity of adverse effects can be increased when Orphenadrine is combined with Ethchlorvynol.
EthopropazineThe risk or severity of adverse effects can be increased when Ethopropazine is combined with Orphenadrine.
EthosuximideEthosuximide may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.
EthosuximideThe risk or severity of adverse effects can be increased when Orphenadrine is combined with Ethosuximide.
EthotoinEthotoin may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.
EthotoinThe risk or severity of adverse effects can be increased when Orphenadrine is combined with Ethotoin.
Ethyl carbamateEthyl carbamate may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.
Ethyl carbamateThe risk or severity of adverse effects can be increased when Orphenadrine is combined with Ethyl carbamate.
Ethyl loflazepateEthyl loflazepate may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.
Ethyl loflazepateThe risk or severity of adverse effects can be increased when Orphenadrine is combined with Ethyl loflazepate.
EthylmorphineEthylmorphine may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.
EthylmorphineThe risk or severity of adverse effects can be increased when Orphenadrine is combined with Ethylmorphine.
EtidocaineEtidocaine may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.
EtidocaineThe risk or severity of adverse effects can be increased when Orphenadrine is combined with Etidocaine.
EtifoxineEtifoxine may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.
EtifoxineThe risk or severity of adverse effects can be increased when Orphenadrine is combined with Etifoxine.
EtizolamEtizolam may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.
EtizolamThe risk or severity of adverse effects can be increased when Orphenadrine is combined with Etizolam.
EtomidateEtomidate may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.
EtomidateThe risk or severity of adverse effects can be increased when Orphenadrine is combined with Etomidate.
EtoperidoneThe risk or severity of adverse effects can be increased when Orphenadrine is combined with Etoperidone.
EtorphineEtorphine may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.
EtorphineThe risk or severity of adverse effects can be increased when Orphenadrine is combined with Etorphine.
EtravirineThe serum concentration of Orphenadrine can be decreased when it is combined with Etravirine.
EzogabineEzogabine may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.
EzogabineThe risk or severity of adverse effects can be increased when Orphenadrine is combined with Ezogabine.
FelbamateFelbamate may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.
FelbamateThe risk or severity of adverse effects can be increased when Orphenadrine is combined with Felbamate.
FencamfamineFencamfamine may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.
FencamfamineThe risk or severity of adverse effects can be increased when Orphenadrine is combined with Fencamfamine.
FenfluramineThe risk or severity of adverse effects can be increased when Orphenadrine is combined with Fenfluramine.
FentanylFentanyl may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.
FentanylThe risk or severity of adverse effects can be increased when Orphenadrine is combined with Fentanyl.
FenthionThe therapeutic efficacy of Orphenadrine can be decreased when used in combination with Fenthion.
FesoterodineThe risk or severity of adverse effects can be increased when Orphenadrine is combined with Fesoterodine.
FexofenadineFexofenadine may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.
FexofenadineThe risk or severity of adverse effects can be increased when Orphenadrine is combined with Fexofenadine.
FlibanserinFlibanserin may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.
FlibanserinThe risk or severity of adverse effects can be increased when Orphenadrine is combined with Flibanserin.
FluconazoleThe metabolism of Orphenadrine can be decreased when combined with Fluconazole.
FludiazepamFludiazepam may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.
FludiazepamThe risk or severity of adverse effects can be increased when Orphenadrine is combined with Fludiazepam.
FlunarizineFlunarizine may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.
FlunarizineThe risk or severity of adverse effects can be increased when Orphenadrine is combined with Flunarizine.
FlunitrazepamFlunitrazepam may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.
FlunitrazepamThe risk or severity of adverse effects can be increased when Orphenadrine is combined with Flunitrazepam.
FluoxetineThe risk or severity of adverse effects can be increased when Orphenadrine is combined with Fluoxetine.
FlupentixolFlupentixol may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.
FlupentixolThe risk or severity of adverse effects can be increased when Orphenadrine is combined with Flupentixol.
FluphenazineFluphenazine may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.
FluphenazineThe risk or severity of adverse effects can be increased when Orphenadrine is combined with Fluphenazine.
FlurazepamFlurazepam may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.
FlurazepamThe risk or severity of adverse effects can be increased when Orphenadrine is combined with Flurazepam.
FluspirileneFluspirilene may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.
FluspirileneThe risk or severity of adverse effects can be increased when Orphenadrine is combined with Fluspirilene.
Fluticasone PropionateFluticasone Propionate may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.
Fluticasone PropionateThe risk or severity of adverse effects can be increased when Orphenadrine is combined with Fluticasone Propionate.
FluvoxamineFluvoxamine may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.
FluvoxamineThe risk or severity of adverse effects can be increased when Orphenadrine is combined with Fluvoxamine.
FosamprenavirThe metabolism of Orphenadrine can be decreased when combined with Fosamprenavir.
FosaprepitantThe serum concentration of Orphenadrine can be increased when it is combined with Fosaprepitant.
FosphenytoinFosphenytoin may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.
FosphenytoinThe risk or severity of adverse effects can be increased when Orphenadrine is combined with Fosphenytoin.
FospropofolFospropofol may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.
FospropofolThe risk or severity of adverse effects can be increased when Orphenadrine is combined with Fospropofol.
Fusidic AcidThe serum concentration of Orphenadrine can be increased when it is combined with Fusidic Acid.
GabapentinGabapentin may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.
GabapentinThe risk or severity of adverse effects can be increased when Orphenadrine is combined with Gabapentin.
gabapentin enacarbilgabapentin enacarbil may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.
gabapentin enacarbilThe risk or severity of adverse effects can be increased when Orphenadrine is combined with gabapentin enacarbil.
GalantamineThe therapeutic efficacy of Orphenadrine can be decreased when used in combination with Galantamine.
Gallamine TriethiodideThe risk or severity of adverse effects can be increased when Gallamine Triethiodide is combined with Orphenadrine.
Gamma Hydroxybutyric AcidGamma Hydroxybutyric Acid may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.
Gamma Hydroxybutyric AcidThe risk or severity of adverse effects can be increased when Orphenadrine is combined with Gamma Hydroxybutyric Acid.
Ginkgo bilobaThe therapeutic efficacy of Orphenadrine can be decreased when used in combination with Ginkgo biloba.
Glucagon recombinantThe risk or severity of adverse effects can be increased when Orphenadrine is combined with Glucagon recombinant.
GlutethimideGlutethimide may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.
GlutethimideThe risk or severity of adverse effects can be increased when Orphenadrine is combined with Glutethimide.
GlycopyrroniumThe risk or severity of adverse effects can be increased when Glycopyrronium is combined with Orphenadrine.
GlycopyrroniumOrphenadrine may increase the anticholinergic activities of Glycopyrronium.
GuanfacineGuanfacine may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.
GuanfacineThe risk or severity of adverse effects can be increased when Orphenadrine is combined with Guanfacine.
HalazepamHalazepam may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.
HalazepamThe risk or severity of adverse effects can be increased when Orphenadrine is combined with Halazepam.
HaloperidolHaloperidol may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.
HaloperidolThe risk or severity of adverse effects can be increased when Orphenadrine is combined with Haloperidol.
HalothaneHalothane may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.
HalothaneThe risk or severity of adverse effects can be increased when Orphenadrine is combined with Halothane.
HeroinHeroin may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.
HeroinThe risk or severity of adverse effects can be increased when Orphenadrine is combined with Heroin.
HexamethoniumThe risk or severity of adverse effects can be increased when Orphenadrine is combined with Hexamethonium.
HexobarbitalHexobarbital may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.
HexobarbitalThe risk or severity of adverse effects can be increased when Orphenadrine is combined with Hexobarbital.
HomatropineThe risk or severity of adverse effects can be increased when Orphenadrine is combined with Homatropine.
Huperzine AThe therapeutic efficacy of Orphenadrine can be decreased when used in combination with Huperzine A.
HydrochlorothiazideThe serum concentration of Hydrochlorothiazide can be increased when it is combined with Orphenadrine.
HydrocodoneHydrocodone may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.
HydrocodoneThe risk or severity of adverse effects can be increased when Orphenadrine is combined with Hydrocodone.
HydroflumethiazideThe serum concentration of Hydroflumethiazide can be increased when it is combined with Orphenadrine.
HydromorphoneHydromorphone may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.
HydromorphoneThe risk or severity of adverse effects can be increased when Orphenadrine is combined with Hydromorphone.
HydroxyzineHydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.
HydroxyzineThe risk or severity of adverse effects can be increased when Orphenadrine is combined with Hydroxyzine.
HyoscyamineThe risk or severity of adverse effects can be increased when Hyoscyamine is combined with Orphenadrine.
IdelalisibThe serum concentration of Orphenadrine can be increased when it is combined with Idelalisib.
IloperidoneIloperidone may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.
IloperidoneThe risk or severity of adverse effects can be increased when Orphenadrine is combined with Iloperidone.
ImatinibThe metabolism of Orphenadrine can be decreased when combined with Imatinib.
ImipramineImipramine may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.
ImipramineThe risk or severity of adverse effects can be increased when Orphenadrine is combined with Imipramine.
IndalpineThe risk or severity of adverse effects can be increased when Orphenadrine is combined with Indalpine.
IndapamideThe serum concentration of Indapamide can be increased when it is combined with Orphenadrine.
IndinavirThe metabolism of Orphenadrine can be decreased when combined with Indinavir.
Ipratropium bromideThe risk or severity of adverse effects can be increased when Ipratropium bromide is combined with Orphenadrine.
IsavuconazoniumThe metabolism of Orphenadrine can be decreased when combined with Isavuconazonium.
IsofluraneIsoflurane may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.
IsofluraneThe risk or severity of adverse effects can be increased when Orphenadrine is combined with Isoflurane.
IsoflurophateThe therapeutic efficacy of Orphenadrine can be decreased when used in combination with Isoflurophate.
IsradipineThe metabolism of Orphenadrine can be decreased when combined with Isradipine.
ItoprideThe therapeutic efficacy of Itopride can be decreased when used in combination with Orphenadrine.
ItraconazoleThe metabolism of Orphenadrine can be decreased when combined with Itraconazole.
IvacaftorThe serum concentration of Orphenadrine can be increased when it is combined with Ivacaftor.
KetamineKetamine may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.
KetamineThe risk or severity of adverse effects can be increased when Orphenadrine is combined with Ketamine.
KetazolamKetazolam may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.
KetazolamThe risk or severity of adverse effects can be increased when Orphenadrine is combined with Ketazolam.
KetobemidoneKetobemidone may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.
KetobemidoneThe risk or severity of adverse effects can be increased when Orphenadrine is combined with Ketobemidone.
KetoconazoleThe metabolism of Orphenadrine can be decreased when combined with Ketoconazole.
LamotrigineLamotrigine may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.
LamotrigineThe risk or severity of adverse effects can be increased when Orphenadrine is combined with Lamotrigine.
LevetiracetamLevetiracetam may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.
LevetiracetamThe risk or severity of adverse effects can be increased when Orphenadrine is combined with Levetiracetam.
LevobupivacaineLevobupivacaine may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.
LevobupivacaineThe risk or severity of adverse effects can be increased when Orphenadrine is combined with Levobupivacaine.
LevocabastineLevocabastine may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.
LevocabastineThe risk or severity of adverse effects can be increased when Orphenadrine is combined with Levocabastine.
LevocetirizineLevocetirizine may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.
LevocetirizineThe risk or severity of adverse effects can be increased when Orphenadrine is combined with Levocetirizine.
LevodopaLevodopa may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.
LevodopaThe risk or severity of adverse effects can be increased when Orphenadrine is combined with Levodopa.
Levomethadyl AcetateLevomethadyl Acetate may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.
Levomethadyl AcetateThe risk or severity of adverse effects can be increased when Orphenadrine is combined with Levomethadyl Acetate.
LevomilnacipranThe risk or severity of adverse effects can be increased when Orphenadrine is combined with Levomilnacipran.
LevorphanolLevorphanol may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.
LevorphanolThe risk or severity of adverse effects can be increased when Orphenadrine is combined with Levorphanol.
LidocaineLidocaine may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.
LidocaineThe risk or severity of adverse effects can be increased when Orphenadrine is combined with Lidocaine.
LithiumLithium may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.
LithiumThe risk or severity of adverse effects can be increased when Orphenadrine is combined with Lithium.
LofentanilLofentanil may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.
LofentanilThe risk or severity of adverse effects can be increased when Orphenadrine is combined with Lofentanil.
LopinavirThe metabolism of Orphenadrine can be decreased when combined with Lopinavir.
LoratadineLoratadine may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.
LoratadineThe risk or severity of adverse effects can be increased when Orphenadrine is combined with Loratadine.
LorazepamLorazepam may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.
LorazepamThe risk or severity of adverse effects can be increased when Orphenadrine is combined with Lorazepam.
LovastatinThe metabolism of Orphenadrine can be decreased when combined with Lovastatin.
LoxapineLoxapine may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.
LoxapineThe risk or severity of adverse effects can be increased when Orphenadrine is combined with Loxapine.
Lu AA21004Lu AA21004 may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.
Lu AA21004The risk or severity of adverse effects can be increased when Orphenadrine is combined with Lu AA21004.
LuliconazoleThe serum concentration of Orphenadrine can be increased when it is combined with Luliconazole.
LurasidoneLurasidone may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.
LurasidoneThe risk or severity of adverse effects can be increased when Orphenadrine is combined with Lurasidone.
Magnesium SulfateMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.
Magnesium SulfateThe risk or severity of adverse effects can be increased when Orphenadrine is combined with Magnesium Sulfate.
MalathionThe therapeutic efficacy of Orphenadrine can be decreased when used in combination with Malathion.
MaprotilineMaprotiline may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.
MaprotilineThe risk or severity of adverse effects can be increased when Orphenadrine is combined with Maprotiline.
MecamylamineThe risk or severity of adverse effects can be increased when Mecamylamine is combined with Orphenadrine.
MeclizineMeclizine may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.
MeclizineThe risk or severity of adverse effects can be increased when Orphenadrine is combined with Meclizine.
MedetomidineMedetomidine may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.
MedetomidineThe risk or severity of adverse effects can be increased when Orphenadrine is combined with Medetomidine.
MefloquineThe therapeutic efficacy of Orphenadrine can be decreased when used in combination with Mefloquine.
MelatoninMelatonin may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.
MelatoninThe risk or severity of adverse effects can be increased when Orphenadrine is combined with Melatonin.
MelperoneMelperone may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.
MelperoneThe risk or severity of adverse effects can be increased when Orphenadrine is combined with Melperone.
MemantineThe therapeutic efficacy of Orphenadrine can be decreased when used in combination with Memantine.
MepivacaineMepivacaine may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.
MepivacaineThe risk or severity of adverse effects can be increased when Orphenadrine is combined with Mepivacaine.
MeprobamateMeprobamate may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.
MeprobamateThe risk or severity of adverse effects can be increased when Orphenadrine is combined with Meprobamate.
MesoridazineMesoridazine may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.
MesoridazineThe risk or severity of adverse effects can be increased when Orphenadrine is combined with Mesoridazine.
MetaxaloneMetaxalone may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.
MetaxaloneThe risk or severity of adverse effects can be increased when Orphenadrine is combined with Metaxalone.
MethadoneMethadone may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.
MethadoneThe risk or severity of adverse effects can be increased when Orphenadrine is combined with Methadone.
Methadyl AcetateMethadyl Acetate may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.
Methadyl AcetateThe risk or severity of adverse effects can be increased when Orphenadrine is combined with Methadyl Acetate.
MethanthelineThe risk or severity of adverse effects can be increased when Methantheline is combined with Orphenadrine.
MethapyrileneMethapyrilene may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.
MethapyrileneThe risk or severity of adverse effects can be increased when Orphenadrine is combined with Methapyrilene.
MethaqualoneMethaqualone may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.
MethaqualoneThe risk or severity of adverse effects can be increased when Orphenadrine is combined with Methaqualone.
MethocarbamolMethocarbamol may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.
MethocarbamolThe risk or severity of adverse effects can be increased when Orphenadrine is combined with Methocarbamol.
MethohexitalMethohexital may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.
MethohexitalThe risk or severity of adverse effects can be increased when Orphenadrine is combined with Methohexital.
MethotrimeprazineMethotrimeprazine may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.
MethotrimeprazineThe risk or severity of adverse effects can be increased when Orphenadrine is combined with Methotrimeprazine.
MethoxyfluraneMethoxyflurane may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.
MethoxyfluraneThe risk or severity of adverse effects can be increased when Orphenadrine is combined with Methoxyflurane.
MethsuximideMethsuximide may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.
MethsuximideThe risk or severity of adverse effects can be increased when Orphenadrine is combined with Methsuximide.
MethyclothiazideThe serum concentration of Methyclothiazide can be increased when it is combined with Orphenadrine.
MethylphenobarbitalMethylphenobarbital may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.
MethylphenobarbitalThe risk or severity of adverse effects can be increased when Orphenadrine is combined with Methylphenobarbital.
MetixeneThe risk or severity of adverse effects can be increased when Orphenadrine is combined with Metixene.
MetolazoneThe serum concentration of Metolazone can be increased when it is combined with Orphenadrine.
MetyrosineOrphenadrine may increase the sedative activities of Metyrosine.
MianserinMianserin may increase the anticholinergic activities of Orphenadrine.
MidazolamMidazolam may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.
MidazolamThe risk or severity of adverse effects can be increased when Orphenadrine is combined with Midazolam.
MifepristoneThe metabolism of Orphenadrine can be decreased when combined with Mifepristone.
MilnacipranThe risk or severity of adverse effects can be increased when Orphenadrine is combined with Milnacipran.
MinaprineThe therapeutic efficacy of Orphenadrine can be decreased when used in combination with Minaprine.
MinocyclineMinocycline may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.
MirabegronThe risk or severity of adverse effects can be increased when Orphenadrine is combined with Mirabegron.
MirtazapineOrphenadrine may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.
MitotaneThe serum concentration of Orphenadrine can be decreased when it is combined with Mitotane.
ModafinilThe serum concentration of Orphenadrine can be decreased when it is combined with Modafinil.
MolindoneMolindone may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.
MolindoneThe risk or severity of adverse effects can be increased when Orphenadrine is combined with Molindone.
MorphineMorphine may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.
MorphineThe risk or severity of adverse effects can be increased when Orphenadrine is combined with Morphine.
N-butylscopolammonium bromideThe risk or severity of adverse effects can be increased when Orphenadrine is combined with N-butylscopolammonium bromide.
NabiloneNabilone may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.
NabiloneOrphenadrine may increase the tachycardic activities of Nabilone.
NafcillinThe serum concentration of Orphenadrine can be decreased when it is combined with Nafcillin.
NalbuphineNalbuphine may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.
NalbuphineThe risk or severity of adverse effects can be increased when Orphenadrine is combined with Nalbuphine.
NefazodoneThe metabolism of Orphenadrine can be decreased when combined with Nefazodone.
NelfinavirThe metabolism of Orphenadrine can be decreased when combined with Nelfinavir.
NeostigmineThe therapeutic efficacy of Orphenadrine can be decreased when used in combination with Neostigmine.
NetupitantThe serum concentration of Orphenadrine can be increased when it is combined with Netupitant.
NevirapineThe metabolism of Orphenadrine can be decreased when combined with Nevirapine.
NilotinibThe metabolism of Orphenadrine can be decreased when combined with Nilotinib.
NitrazepamNitrazepam may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.
NitrazepamThe risk or severity of adverse effects can be increased when Orphenadrine is combined with Nitrazepam.
Nitrous oxideNitrous oxide may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.
Nitrous oxideThe risk or severity of adverse effects can be increased when Orphenadrine is combined with Nitrous oxide.
NormethadoneNormethadone may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.
NormethadoneThe risk or severity of adverse effects can be increased when Orphenadrine is combined with Normethadone.
NortriptylineNortriptyline may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.
NortriptylineThe risk or severity of adverse effects can be increased when Orphenadrine is combined with Nortriptyline.
NVA237The risk or severity of adverse effects can be increased when Orphenadrine is combined with NVA237.
OlanzapineOlanzapine may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.
OlanzapineThe risk or severity of adverse effects can be increased when Orphenadrine is combined with Olanzapine.
OlaparibThe metabolism of Orphenadrine can be decreased when combined with Olaparib.
OlopatadineOlopatadine may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.
OlopatadineThe risk or severity of adverse effects can be increased when Orphenadrine is combined with Olopatadine.
OndansetronOndansetron may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.
OndansetronThe risk or severity of adverse effects can be increased when Orphenadrine is combined with Ondansetron.
OpiumOpium may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.
OpiumThe risk or severity of adverse effects can be increased when Orphenadrine is combined with Opium.
OsanetantOsanetant may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.
OsanetantThe risk or severity of adverse effects can be increased when Orphenadrine is combined with Osanetant.
OsimertinibThe serum concentration of Orphenadrine can be increased when it is combined with Osimertinib.
OxazepamOxazepam may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.
OxazepamThe risk or severity of adverse effects can be increased when Orphenadrine is combined with Oxazepam.
OxprenololOxprenolol may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.
OxprenololThe risk or severity of adverse effects can be increased when Orphenadrine is combined with Oxprenolol.
OxybuprocaineOxybuprocaine may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.
OxybuprocaineThe risk or severity of adverse effects can be increased when Orphenadrine is combined with Oxybuprocaine.
OxybutyninThe risk or severity of adverse effects can be increased when Oxybutynin is combined with Orphenadrine.
OxycodoneOxycodone may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.
OxycodoneThe risk or severity of adverse effects can be increased when Orphenadrine is combined with Oxycodone.
OxymorphoneOxymorphone may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.
OxymorphoneThe risk or severity of adverse effects can be increased when Orphenadrine is combined with Oxymorphone.
OxyphenoniumThe risk or severity of adverse effects can be increased when Oxyphenonium is combined with Orphenadrine.
PalbociclibThe serum concentration of Orphenadrine can be increased when it is combined with Palbociclib.
PaliperidonePaliperidone may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.
PaliperidoneThe risk or severity of adverse effects can be increased when Orphenadrine is combined with Paliperidone.
PancuroniumThe risk or severity of adverse effects can be increased when Orphenadrine is combined with Pancuronium.
ParaldehydeParaldehyde may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.
ParoxetineThe risk or severity of adverse effects can be increased when Orphenadrine is combined with Paroxetine.
PentazocinePentazocine may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.
PentazocineThe risk or severity of adverse effects can be increased when Orphenadrine is combined with Pentazocine.
PentobarbitalPentobarbital may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.
PentobarbitalThe risk or severity of adverse effects can be increased when Orphenadrine is combined with Pentobarbital.
PentoliniumThe risk or severity of adverse effects can be increased when Pentolinium is combined with Orphenadrine.
PerampanelPerampanel may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.
PerampanelThe risk or severity of adverse effects can be increased when Orphenadrine is combined with Perampanel.
PerospironePerospirone may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.
PerospironeThe risk or severity of adverse effects can be increased when Orphenadrine is combined with Perospirone.
PerphenazinePerphenazine may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.
PerphenazineThe risk or severity of adverse effects can be increased when Orphenadrine is combined with Perphenazine.
PethidinePethidine may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.
PethidineThe risk or severity of adverse effects can be increased when Orphenadrine is combined with Pethidine.
PhenobarbitalPhenobarbital may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.
PhenobarbitalThe risk or severity of adverse effects can be increased when Orphenadrine is combined with Phenobarbital.
PhenoxyethanolPhenoxyethanol may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.
PhenoxyethanolThe risk or severity of adverse effects can be increased when Orphenadrine is combined with Phenoxyethanol.
PhenytoinPhenytoin may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.
PhenytoinThe risk or severity of adverse effects can be increased when Orphenadrine is combined with Phenytoin.
PhysostigmineThe therapeutic efficacy of Orphenadrine can be decreased when used in combination with Physostigmine.
PimozidePimozide may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.
PimozideThe risk or severity of adverse effects can be increased when Orphenadrine is combined with Pimozide.
PipamperonePipamperone may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.
PipamperoneThe risk or severity of adverse effects can be increased when Orphenadrine is combined with Pipamperone.
PipecuroniumThe risk or severity of adverse effects can be increased when Orphenadrine is combined with Pipecuronium.
PipotiazinePipotiazine may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.
PipotiazineThe risk or severity of adverse effects can be increased when Orphenadrine is combined with Pipotiazine.
PirenzepineThe risk or severity of adverse effects can be increased when Pirenzepine is combined with Orphenadrine.
PizotifenPizotifen may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.
PizotifenThe risk or severity of adverse effects can be increased when Orphenadrine is combined with Pizotifen.
PolythiazideThe serum concentration of Polythiazide can be increased when it is combined with Orphenadrine.
PomalidomidePomalidomide may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.
PomalidomideThe risk or severity of adverse effects can be increased when Orphenadrine is combined with Pomalidomide.
PosaconazoleThe metabolism of Orphenadrine can be decreased when combined with Posaconazole.
Potassium ChlorideOrphenadrine may increase the ulcerogenic activities of Potassium Chloride.
PramipexoleOrphenadrine may increase the sedative activities of Pramipexole.
PramlintidePramlintide may increase the anticholinergic activities of Orphenadrine.
PramocainePramocaine may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.
PramocaineThe risk or severity of adverse effects can be increased when Orphenadrine is combined with Pramocaine.
PrazepamPrazepam may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.
PrazepamThe risk or severity of adverse effects can be increased when Orphenadrine is combined with Prazepam.
PregabalinPregabalin may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.
PregabalinThe risk or severity of adverse effects can be increased when Orphenadrine is combined with Pregabalin.
PrilocainePrilocaine may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.
PrilocaineThe risk or severity of adverse effects can be increased when Orphenadrine is combined with Prilocaine.
PrimidonePrimidone may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.
PrimidoneThe risk or severity of adverse effects can be increased when Orphenadrine is combined with Primidone.
ProcaineProcaine may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.
ProcaineThe risk or severity of adverse effects can be increased when Orphenadrine is combined with Procaine.
ProchlorperazineProchlorperazine may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.
ProchlorperazineThe risk or severity of adverse effects can be increased when Orphenadrine is combined with Prochlorperazine.
ProcyclidineThe risk or severity of adverse effects can be increased when Procyclidine is combined with Orphenadrine.
PromazinePromazine may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.
PromazineThe risk or severity of adverse effects can be increased when Orphenadrine is combined with Promazine.
PromethazinePromethazine may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.
PromethazineThe risk or severity of adverse effects can be increased when Orphenadrine is combined with Promethazine.
PropanthelineThe risk or severity of adverse effects can be increased when Propantheline is combined with Orphenadrine.
ProparacaineProparacaine may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.
ProparacaineThe risk or severity of adverse effects can be increased when Orphenadrine is combined with Proparacaine.
PropofolPropofol may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.
PropofolThe risk or severity of adverse effects can be increased when Orphenadrine is combined with Propofol.
PropoxycainePropoxycaine may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.
PropoxycaineThe risk or severity of adverse effects can be increased when Orphenadrine is combined with Propoxycaine.
ProtriptylineProtriptyline may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.
ProtriptylineThe risk or severity of adverse effects can be increased when Orphenadrine is combined with Protriptyline.
PSD502PSD502 may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.
PSD502The risk or severity of adverse effects can be increased when Orphenadrine is combined with PSD502.
PyridostigmineThe therapeutic efficacy of Orphenadrine can be decreased when used in combination with Pyridostigmine.
QuazepamQuazepam may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.
QuazepamThe risk or severity of adverse effects can be increased when Orphenadrine is combined with Quazepam.
QuetiapineQuetiapine may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.
QuetiapineThe risk or severity of adverse effects can be increased when Orphenadrine is combined with Quetiapine.
QuinethazoneThe serum concentration of Quinethazone can be increased when it is combined with Orphenadrine.
QuinidineThe risk or severity of adverse effects can be increased when Quinidine is combined with Orphenadrine.
RamelteonRamelteon may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.
RamelteonThe risk or severity of adverse effects can be increased when Orphenadrine is combined with Ramelteon.
RamosetronOrphenadrine may increase the constipating activities of Ramosetron.
RanolazineThe metabolism of Orphenadrine can be decreased when combined with Ranolazine.
RemifentanilRemifentanil may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.
RemifentanilThe risk or severity of adverse effects can be increased when Orphenadrine is combined with Remifentanil.
RemoxiprideRemoxipride may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.
RemoxiprideThe risk or severity of adverse effects can be increased when Orphenadrine is combined with Remoxipride.
ReserpineReserpine may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.
ReserpineThe risk or severity of adverse effects can be increased when Orphenadrine is combined with Reserpine.
RifabutinThe metabolism of Orphenadrine can be increased when combined with Rifabutin.
RifampicinThe metabolism of Orphenadrine can be increased when combined with Rifampicin.
RifapentineThe metabolism of Orphenadrine can be increased when combined with Rifapentine.
RisperidoneRisperidone may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.
RisperidoneThe risk or severity of adverse effects can be increased when Orphenadrine is combined with Risperidone.
RitonavirThe metabolism of Orphenadrine can be decreased when combined with Ritonavir.
RivastigmineThe therapeutic efficacy of Orphenadrine can be decreased when used in combination with Rivastigmine.
RomifidineRomifidine may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.
RomifidineThe risk or severity of adverse effects can be increased when Orphenadrine is combined with Romifidine.
RopiniroleOrphenadrine may increase the sedative activities of Ropinirole.
RopivacaineRopivacaine may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.
RopivacaineThe risk or severity of adverse effects can be increased when Orphenadrine is combined with Ropivacaine.
RotigotineOrphenadrine may increase the sedative activities of Rotigotine.
RufinamideThe risk or severity of adverse effects can be increased when Rufinamide is combined with Orphenadrine.
S-EthylisothioureaS-Ethylisothiourea may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.
S-EthylisothioureaThe risk or severity of adverse effects can be increased when Orphenadrine is combined with S-Ethylisothiourea.
SaquinavirThe metabolism of Orphenadrine can be decreased when combined with Saquinavir.
ScopolamineScopolamine may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.
ScopolamineThe risk or severity of adverse effects can be increased when Orphenadrine is combined with Scopolamine.
Scopolamine butylbromideThe risk or severity of adverse effects can be increased when Orphenadrine is combined with Scopolamine butylbromide.
SecobarbitalSecobarbital may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.
SecobarbitalThe risk or severity of adverse effects can be increased when Orphenadrine is combined with Secobarbital.
SecretinThe therapeutic efficacy of Secretin can be decreased when used in combination with Orphenadrine.
SertindoleSertindole may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.
SertindoleThe risk or severity of adverse effects can be increased when Orphenadrine is combined with Sertindole.
SertralineThe risk or severity of adverse effects can be increased when Orphenadrine is combined with Sertraline.
SevofluraneSevoflurane may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.
SevofluraneThe risk or severity of adverse effects can be increased when Orphenadrine is combined with Sevoflurane.
SildenafilThe metabolism of Orphenadrine can be decreased when combined with Sildenafil.
SiltuximabThe serum concentration of Orphenadrine can be decreased when it is combined with Siltuximab.
SimeprevirThe serum concentration of Orphenadrine can be increased when it is combined with Simeprevir.
Sodium oxybateSodium oxybate may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.
Sodium oxybateThe risk or severity of adverse effects can be increased when Orphenadrine is combined with Sodium oxybate.
SolifenacinThe risk or severity of adverse effects can be increased when Orphenadrine is combined with Solifenacin.
St. John's WortThe serum concentration of Orphenadrine can be decreased when it is combined with St. John&#39;s Wort.
StiripentolStiripentol may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.
StiripentolThe risk or severity of adverse effects can be increased when Orphenadrine is combined with Stiripentol.
SufentanilSufentanil may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.
SufentanilThe risk or severity of adverse effects can be increased when Orphenadrine is combined with Sufentanil.
SulfisoxazoleThe metabolism of Orphenadrine can be decreased when combined with Sulfisoxazole.
SulpirideSulpiride may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.
SulpirideThe therapeutic efficacy of Sulpiride can be decreased when used in combination with Orphenadrine.
SuvorexantSuvorexant may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.
SuvorexantThe risk or severity of adverse effects can be increased when Orphenadrine is combined with Suvorexant.
TacrineThe therapeutic efficacy of Orphenadrine can be decreased when used in combination with Tacrine.
TapentadolTapentadol may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.
TapentadolThe risk or severity of adverse effects can be increased when Orphenadrine is combined with Tapentadol.
TasimelteonTasimelteon may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.
TasimelteonThe risk or severity of adverse effects can be increased when Orphenadrine is combined with Tasimelteon.
TelaprevirThe metabolism of Orphenadrine can be decreased when combined with Telaprevir.
TelithromycinThe metabolism of Orphenadrine can be decreased when combined with Telithromycin.
TemazepamTemazepam may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.
TemazepamThe risk or severity of adverse effects can be increased when Orphenadrine is combined with Temazepam.
TetrabenazineTetrabenazine may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.
TetrabenazineThe risk or severity of adverse effects can be increased when Orphenadrine is combined with Tetrabenazine.
TetracaineTetracaine may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.
TetracaineThe risk or severity of adverse effects can be increased when Orphenadrine is combined with Tetracaine.
TetrodotoxinTetrodotoxin may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.
TetrodotoxinThe risk or severity of adverse effects can be increased when Orphenadrine is combined with Tetrodotoxin.
ThalidomideThalidomide may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.
ThiamylalThiamylal may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.
ThiamylalThe risk or severity of adverse effects can be increased when Orphenadrine is combined with Thiamylal.
ThiopentalThiopental may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.
ThiopentalThe risk or severity of adverse effects can be increased when Orphenadrine is combined with Thiopental.
ThioridazineThioridazine may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.
ThioridazineThe risk or severity of adverse effects can be increased when Orphenadrine is combined with Thioridazine.
ThiothixeneThiothixene may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.
ThiothixeneThe risk or severity of adverse effects can be increased when Orphenadrine is combined with Thiothixene.
TiagabineTiagabine may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.
TiagabineThe risk or severity of adverse effects can be increased when Orphenadrine is combined with Tiagabine.
TiclopidineThe metabolism of Orphenadrine can be decreased when combined with Ticlopidine.
TiletamineTiletamine may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.
TiletamineThe risk or severity of adverse effects can be increased when Orphenadrine is combined with Tiletamine.
TiotropiumOrphenadrine may increase the anticholinergic activities of Tiotropium.
TiotropiumThe risk or severity of adverse effects can be increased when Tiotropium is combined with Orphenadrine.
TizanidineTizanidine may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.
TizanidineThe risk or severity of adverse effects can be increased when Orphenadrine is combined with Tizanidine.
TocilizumabThe serum concentration of Orphenadrine can be decreased when it is combined with Tocilizumab.
TolcaponeTolcapone may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.
TolcaponeThe risk or severity of adverse effects can be increased when Orphenadrine is combined with Tolcapone.
TolterodineThe risk or severity of adverse effects can be increased when Tolterodine is combined with Orphenadrine.
TopiramateTopiramate may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.
TopiramateThe risk or severity of adverse effects can be increased when Orphenadrine is combined with Topiramate.
TramadolTramadol may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.
TramadolThe risk or severity of adverse effects can be increased when Orphenadrine is combined with Tramadol.
Trans-2-PhenylcyclopropylamineTrans-2-Phenylcyclopropylamine may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.
Trans-2-PhenylcyclopropylamineThe risk or severity of adverse effects can be increased when Orphenadrine is combined with Trans-2-Phenylcyclopropylamine.
TranylcypromineTranylcypromine may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.
TranylcypromineThe risk or severity of adverse effects can be increased when Orphenadrine is combined with Tranylcypromine.
TrazodoneTrazodone may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.
TrazodoneThe risk or severity of adverse effects can be increased when Orphenadrine is combined with Trazodone.
TriazolamTriazolam may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.
TriazolamThe risk or severity of adverse effects can be increased when Orphenadrine is combined with Triazolam.
TrichlorfonThe therapeutic efficacy of Orphenadrine can be decreased when used in combination with Trichlorfon.
TrichlormethiazideThe serum concentration of Trichlormethiazide can be increased when it is combined with Orphenadrine.
TrifluoperazineTrifluoperazine may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.
TrifluoperazineThe risk or severity of adverse effects can be increased when Orphenadrine is combined with Trifluoperazine.
TriflupromazineTriflupromazine may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.
TriflupromazineThe risk or severity of adverse effects can be increased when Orphenadrine is combined with Triflupromazine.
TrihexyphenidylThe risk or severity of adverse effects can be increased when Trihexyphenidyl is combined with Orphenadrine.
TrimethaphanThe risk or severity of adverse effects can be increased when Trimethaphan is combined with Orphenadrine.
TrimipramineTrimipramine may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.
TrimipramineThe risk or severity of adverse effects can be increased when Orphenadrine is combined with Trimipramine.
TriprolidineTriprolidine may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.
TriprolidineThe risk or severity of adverse effects can be increased when Orphenadrine is combined with Triprolidine.
TropicamideThe risk or severity of adverse effects can be increased when Tropicamide is combined with Orphenadrine.
TrospiumThe risk or severity of adverse effects can be increased when Trospium is combined with Orphenadrine.
TubocurarineThe risk or severity of adverse effects can be increased when Orphenadrine is combined with Tubocurarine.
UmeclidiniumUmeclidinium may increase the anticholinergic activities of Orphenadrine.
UmeclidiniumThe risk or severity of adverse effects can be increased when Orphenadrine is combined with Umeclidinium.
Valproic AcidValproic Acid may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.
Valproic AcidThe risk or severity of adverse effects can be increased when Orphenadrine is combined with Valproic Acid.
VecuroniumThe risk or severity of adverse effects can be increased when Orphenadrine is combined with Vecuronium.
VenlafaxineThe metabolism of Orphenadrine can be decreased when combined with Venlafaxine.
VerapamilThe metabolism of Orphenadrine can be decreased when combined with Verapamil.
VigabatrinVigabatrin may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.
VigabatrinThe risk or severity of adverse effects can be increased when Orphenadrine is combined with Vigabatrin.
VilazodoneThe risk or severity of adverse effects can be increased when Orphenadrine is combined with Vilazodone.
VoriconazoleThe metabolism of Orphenadrine can be decreased when combined with Voriconazole.
VortioxetineVortioxetine may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.
VortioxetineThe risk or severity of adverse effects can be increased when Orphenadrine is combined with Vortioxetine.
XylazineXylazine may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.
XylazineThe risk or severity of adverse effects can be increased when Orphenadrine is combined with Xylazine.
ZaleplonZaleplon may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.
ZaleplonThe risk or severity of adverse effects can be increased when Orphenadrine is combined with Zaleplon.
ZiconotideZiconotide may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.
ZiconotideThe risk or severity of adverse effects can be increased when Orphenadrine is combined with Ziconotide.
ZimelidineThe risk or severity of adverse effects can be increased when Orphenadrine is combined with Zimelidine.
ZiprasidoneZiprasidone may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.
ZiprasidoneThe risk or severity of adverse effects can be increased when Orphenadrine is combined with Ziprasidone.
ZolazepamZolazepam may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.
ZolazepamThe risk or severity of adverse effects can be increased when Orphenadrine is combined with Zolazepam.
ZolpidemZolpidem may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.
ZolpidemThe risk or severity of adverse effects can be increased when Orphenadrine is combined with Zolpidem.
ZonisamideZonisamide may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.
ZonisamideThe risk or severity of adverse effects can be increased when Orphenadrine is combined with Zonisamide.
ZopicloneZopiclone may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.
ZopicloneThe risk or severity of adverse effects can be increased when Orphenadrine is combined with Zopiclone.
ZotepineZotepine may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.
ZotepineThe risk or severity of adverse effects can be increased when Orphenadrine is combined with Zotepine.
ZuclopenthixolZuclopenthixol may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.
ZuclopenthixolThe risk or severity of adverse effects can be increased when Orphenadrine is combined with Zuclopenthixol.
Food Interactions
  • Take without regard to meals. Avoid alcohol.

Targets

Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
antagonist
General Function:
Nmda glutamate receptor activity
Specific Function:
NMDA receptor subtype of glutamate-gated ion channels with high calcium permeability and voltage-dependent sensitivity to magnesium. Mediated by glycine.
Gene Name:
GRIN2D
Uniprot ID:
O15399
Molecular Weight:
143750.685 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284 ]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423 ]
  3. Kornhuber J, Parsons CG, Hartmann S, Retz W, Kamolz S, Thome J, Riederer P: Orphenadrine is an uncompetitive N-methyl-D-aspartate (NMDA) receptor antagonist: binding and patch clamp studies. J Neural Transm Gen Sect. 1995;102(3):237-46. [PubMed:8788072 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
antagonist
General Function:
Voltage-gated cation channel activity
Specific Function:
NMDA receptor subtype of glutamate-gated ion channels with high calcium permeability and voltage-dependent sensitivity to magnesium. Mediated by glycine. This protein plays a key role in synaptic plasticity, synaptogenesis, excitotoxicity, memory acquisition and learning. It mediates neuronal functions in glutamate neurotransmission. Is involved in the cell surface targeting of NMDA receptors (...
Gene Name:
GRIN1
Uniprot ID:
Q05586
Molecular Weight:
105371.945 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284 ]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423 ]
  3. Kornhuber J, Parsons CG, Hartmann S, Retz W, Kamolz S, Thome J, Riederer P: Orphenadrine is an uncompetitive N-methyl-D-aspartate (NMDA) receptor antagonist: binding and patch clamp studies. J Neural Transm Gen Sect. 1995;102(3):237-46. [PubMed:8788072 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
antagonist
General Function:
Nmda glutamate receptor activity
Specific Function:
NMDA receptor subtype of glutamate-gated ion channels with reduced single-channel conductance, low calcium permeability and low voltage-dependent sensitivity to magnesium. Mediated by glycine.
Gene Name:
GRIN3B
Uniprot ID:
O60391
Molecular Weight:
112990.98 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284 ]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423 ]
  3. Kornhuber J, Parsons CG, Hartmann S, Retz W, Kamolz S, Thome J, Riederer P: Orphenadrine is an uncompetitive N-methyl-D-aspartate (NMDA) receptor antagonist: binding and patch clamp studies. J Neural Transm Gen Sect. 1995;102(3):237-46. [PubMed:8788072 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
antagonist
General Function:
Protein phosphatase 2a binding
Specific Function:
NMDA receptor subtype of glutamate-gated ion channels with reduced single-channel conductance, low calcium permeability and low voltage-dependent sensitivity to magnesium. Mediated by glycine. May play a role in the development of dendritic spines. May play a role in PPP2CB-NMDAR mediated signaling mechanism (By similarity).
Gene Name:
GRIN3A
Uniprot ID:
Q8TCU5
Molecular Weight:
125464.07 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284 ]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423 ]
  3. Kornhuber J, Parsons CG, Hartmann S, Retz W, Kamolz S, Thome J, Riederer P: Orphenadrine is an uncompetitive N-methyl-D-aspartate (NMDA) receptor antagonist: binding and patch clamp studies. J Neural Transm Gen Sect. 1995;102(3):237-46. [PubMed:8788072 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
antagonist
General Function:
Histamine receptor activity
Specific Function:
In peripheral tissues, the H1 subclass of histamine receptors mediates the contraction of smooth muscles, increase in capillary permeability due to contraction of terminal venules, and catecholamine release from adrenal medulla, as well as mediating neurotransmission in the central nervous system.
Gene Name:
HRH1
Uniprot ID:
P35367
Molecular Weight:
55783.61 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284 ]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423 ]
  3. Rumore MM, Schlichting DA: Analgesic effects of antihistaminics. Life Sci. 1985 Feb 4;36(5):403-16. [PubMed:2578597 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
inhibitor
General Function:
Norepinephrine:sodium symporter activity
Specific Function:
Amine transporter. Terminates the action of noradrenaline by its high affinity sodium-dependent reuptake into presynaptic terminals.
Gene Name:
SLC6A2
Uniprot ID:
P23975
Molecular Weight:
69331.42 Da
References
  1. Pubill D, Canudas AM, Pallas M, Sureda FX, Escubedo E, Camins A, Camarasa J: Assessment of the adrenergic effects of orphenadrine in rat vas deferens. J Pharm Pharmacol. 1999 Mar;51(3):307-12. [PubMed:10344632 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Voltage-gated sodium channel activity
Specific Function:
Tetrodotoxin-resistant channel that mediates the voltage-dependent sodium ion permeability of excitable membranes. Assuming opened or closed conformations in response to the voltage difference across the membrane, the protein forms a sodium-selective channel through which sodium ions may pass in accordance with their electrochemical gradient. Plays a role in neuropathic pain mechanisms.
Gene Name:
SCN10A
Uniprot ID:
Q9Y5Y9
Molecular Weight:
220623.605 Da
References
  1. Pubill D, Canudas AM, Pallas M, Sureda FX, Escubedo E, Camins A, Camarasa J: Assessment of the adrenergic effects of orphenadrine in rat vas deferens. J Pharm Pharmacol. 1999 Mar;51(3):307-12. [PubMed:10344632 ]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitorinducer
General Function:
Steroid hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics. Acts as a 1,4-cineole 2-exo-monooxygenase.
Gene Name:
CYP2B6
Uniprot ID:
P20813
Molecular Weight:
56277.81 Da
References
  1. Peng FC, Lin Wu SW: Metabolism of territrem a in liver microsomes from male wistar rats: 3. Cytochrome p-450 isoforms catalyzing tra metabolism. J Toxicol Environ Health A. 2002 Dec 27;65(24):2163-75. [PubMed:12515593 ]
  2. Lin Wu SW, Jean WC, Peng FC, Edwards RJ: Cytochrome P-4503A1 catalyzes the formation of MA1 from territrem a in liver microsomes of 7-week-old female Wistar rats. J Toxicol Environ Health A. 2003 Mar 14;66(5):453-67. [PubMed:12712632 ]
  3. Chang TK, Weber GF, Crespi CL, Waxman DJ: Differential activation of cyclophosphamide and ifosphamide by cytochromes P-450 2B and 3A in human liver microsomes. Cancer Res. 1993 Dec 1;53(23):5629-37. [PubMed:8242617 ]
  4. Stresser DM, Dehal SS, Kupfer D: Ring hydroxylation of [o-3H]methoxychlor as a probe for liver microsomal CYP2B activity: potential for in vivo CYP2B assay. Anal Biochem. 1996 Jan 1;233(1):100-7. [PubMed:8789153 ]
  5. Murray M, Fiala-Beer E, Sutton D: Upregulation of cytochromes P450 2B in rat liver by orphenadrine. Br J Pharmacol. 2003 Jun;139(4):787-96. [PubMed:12813002 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Vitamin d3 25-hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation reactions (e.g. caffeine 8-oxidation, omeprazole sulphoxidation, midazolam 1'-hydroxylation and midazolam 4-hydroxylation) of structurally unrelated compounds, including steroids, fatty acids, and xenobiot...
Gene Name:
CYP3A4
Uniprot ID:
P08684
Molecular Weight:
57342.67 Da
References
  1. Roos PH, Mahnke A: Metabolite complex formation of orphenadrine with cytochrome P450. Involvement of CYP2C11 and CYP3A isozymes. Biochem Pharmacol. 1996 Jul 12;52(1):73-84. [PubMed:8678911 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
General Function:
Steroid hydroxylase activity
Specific Function:
Metabolizes several precarcinogens, drugs, and solvents to reactive metabolites. Inactivates a number of drugs and xenobiotics and also bioactivates many xenobiotic substrates to their hepatotoxic or carcinogenic forms.
Gene Name:
CYP2E1
Uniprot ID:
P05181
Molecular Weight:
56848.42 Da
References
  1. Sai Y, Dai R, Yang TJ, Krausz KW, Gonzalez FJ, Gelboin HV, Shou M: Assessment of specificity of eight chemical inhibitors using cDNA-expressed cytochromes P450. Xenobiotica. 2000 Apr;30(4):327-43. [PubMed:10821163 ]
Comments
comments powered by Disqus
Drug created on June 13, 2005 07:24 / Updated on August 17, 2016 12:23